[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat",
    "summary": "The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's sell-off despite upbeat data on economic growth.",
    "url": "https://finnhub.io/api/news?id=e85e292d5fc4aacadcac987aa9771ff3e40cf4bae9bc84ab5281b12028ff5502",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734644658,
      "headline": "S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat",
      "id": 132059998,
      "image": "https://www.investopedia.com/thmb/gKQgfpi97bBTaUaR5dfhEpcYGv0=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2155206502-5a8269261f8e477fb14ff4b861a0c5ab.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's sell-off despite upbeat data on economic growth.",
      "url": "https://finnhub.io/api/news?id=e85e292d5fc4aacadcac987aa9771ff3e40cf4bae9bc84ab5281b12028ff5502"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
    "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
    "url": "https://finnhub.io/api/news?id=28537cacbff90acc7997934f9cc22fbf4ee418f0d7155fa5427c26116737906e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734643174,
      "headline": "Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
      "id": 132061462,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
      "url": "https://finnhub.io/api/news?id=28537cacbff90acc7997934f9cc22fbf4ee418f0d7155fa5427c26116737906e"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’",
    "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious […]",
    "url": "https://finnhub.io/api/news?id=eed13949b150389a2183134b36c753e4b46ff216ef7549795f9e19752540d1a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734642319,
      "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’",
      "id": 132061463,
      "image": "https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious […]",
      "url": "https://finnhub.io/api/news?id=eed13949b150389a2183134b36c753e4b46ff216ef7549795f9e19752540d1a1"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?",
    "summary": "On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically significant and clinically mean",
    "url": "https://finnhub.io/api/news?id=af95b2e315ebeabd386513625fb4d6e445db6e9d127389ee7b9ac56de510df6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734631592,
      "headline": "Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?",
      "id": 132055336,
      "image": "https://media.zenfs.com/en/Benzinga/66f98a38463887e6a39061b6ed232033",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically significant and clinically mean",
      "url": "https://finnhub.io/api/news?id=af95b2e315ebeabd386513625fb4d6e445db6e9d127389ee7b9ac56de510df6e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Dives 13% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
    "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
    "url": "https://finnhub.io/api/news?id=fdd940e4092cd7ddb159930e1418d4aec16ef704cb2f4fabbe85d1a97a2fee20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734630394,
      "headline": "Vertex Dives 13% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
      "id": 132055338,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
      "url": "https://finnhub.io/api/news?id=fdd940e4092cd7ddb159930e1418d4aec16ef704cb2f4fabbe85d1a97a2fee20"
    }
  },
  {
    "ts": null,
    "headline": "Accenture, Robinhood and Coinbase, Vertex: Market Minute",
    "summary": "Yahoo Finance host Rachelle Akuffo dives into three stories from several of the top trending stock tickers on the Yahoo Finance platform. Accenture (ACN) shares are popping after topping its fiscal first quarter earnings estimates. Brokerage site Robinhood Markets (HOOD) and crypto exchange Coinbase Global (COIN) see their stocks move higher amid bitcoin's recent volatility (BTC-USD). Lastly, Vertex Pharmaceuticals (VRTX) shares are dropping Thursday morning in response to its Phase 2 trial results for its new non-opioid painkiller. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=147e45ae4b161e4c6b4e511f8aae60faa590af9f5e338b4e87b79541bb41ade9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734627702,
      "headline": "Accenture, Robinhood and Coinbase, Vertex: Market Minute",
      "id": 132054347,
      "image": "https://s.yimg.com/ny/api/res/1.2/A1IJhRrCRNfCTTYuzKRuIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/ddc95d80-be2a-11ef-9dff-1bd76624dea6",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Rachelle Akuffo dives into three stories from several of the top trending stock tickers on the Yahoo Finance platform. Accenture (ACN) shares are popping after topping its fiscal first quarter earnings estimates. Brokerage site Robinhood Markets (HOOD) and crypto exchange Coinbase Global (COIN) see their stocks move higher amid bitcoin's recent volatility (BTC-USD). Lastly, Vertex Pharmaceuticals (VRTX) shares are dropping Thursday morning in response to its Phase 2 trial results for its new non-opioid painkiller. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=147e45ae4b161e4c6b4e511f8aae60faa590af9f5e338b4e87b79541bb41ade9"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d9e2452c8b4fcee4fd47ac34fb470d9abccfbf392f2eda3b51826cc2b7db2fdb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626460,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 132148893,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d9e2452c8b4fcee4fd47ac34fb470d9abccfbf392f2eda3b51826cc2b7db2fdb"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
    "summary": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
    "url": "https://finnhub.io/api/news?id=f159582f43343fe22cee891d5aa737f9ad960c7090022b84b39c4c98966ed842",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734625008,
      "headline": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
      "id": 132063917,
      "image": "",
      "related": "VRTX",
      "source": "DowJones",
      "summary": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
      "url": "https://finnhub.io/api/news?id=f159582f43343fe22cee891d5aa737f9ad960c7090022b84b39c4c98966ed842"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise.",
    "summary": "The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.",
    "url": "https://finnhub.io/api/news?id=0bd70feff850e1befa4461e40c750950ce6f1f50e3fa567c039adacf719d8e9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734622980,
      "headline": "Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise.",
      "id": 132055340,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.",
      "url": "https://finnhub.io/api/news?id=0bd70feff850e1befa4461e40c750950ce6f1f50e3fa567c039adacf719d8e9d"
    }
  },
  {
    "ts": null,
    "headline": "Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic",
    "summary": "The non-opioid breakthrough stumbles in mid-stage testing, sending Vertex shares into a free fall.",
    "url": "https://finnhub.io/api/news?id=2bffb2184268d3c40064fbc7f7b3e5853dd9abbba5d5c3af69fe717a7ec5847d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734622430,
      "headline": "Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic",
      "id": 132055341,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/97231fca20cee40f16c68627e6914f7a",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The non-opioid breakthrough stumbles in mid-stage testing, sending Vertex shares into a free fall.",
      "url": "https://finnhub.io/api/news?id=2bffb2184268d3c40064fbc7f7b3e5853dd9abbba5d5c3af69fe717a7ec5847d"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results",
    "summary": "Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.",
    "url": "https://finnhub.io/api/news?id=63b653d1a0119e99c23c6cb76838184445c865f030a07ab4036e98d78032859e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734621637,
      "headline": "Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results",
      "id": 132055343,
      "image": "https://www.investopedia.com/thmb/u1Zqp9sw_v7VhvkjVhy25Xqk_zM=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1763769061-1faa7bf1d32e425a96a3857c3a98ef93.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.",
      "url": "https://finnhub.io/api/news?id=63b653d1a0119e99c23c6cb76838184445c865f030a07ab4036e98d78032859e"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3",
    "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third quarter 2024, investor letter. A copy of the letter can be downloaded here. The portfolio slightly underperformed its benchmark index in the third quarter following a robust first half of the year. Performance was impacted by volatility, especially towards the […]",
    "url": "https://finnhub.io/api/news?id=1396bdfc09f042ee4f2eb79c7049039dd8c42d54250f5a54656434845f8efa9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734617786,
      "headline": "Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3",
      "id": 132055344,
      "image": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third quarter 2024, investor letter. A copy of the letter can be downloaded here. The portfolio slightly underperformed its benchmark index in the third quarter following a robust first half of the year. Performance was impacted by volatility, especially towards the […]",
      "url": "https://finnhub.io/api/news?id=1396bdfc09f042ee4f2eb79c7049039dd8c42d54250f5a54656434845f8efa9b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.",
    "summary": "Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.",
    "url": "https://finnhub.io/api/news?id=552d17c9148ff36d616578ade113f585a308a296f8a0ce258521441032dad3b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734613580,
      "headline": "Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.",
      "id": 132055345,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.",
      "url": "https://finnhub.io/api/news?id=552d17c9148ff36d616578ade113f585a308a296f8a0ce258521441032dad3b8"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy",
    "summary": "BOSTON, December 19, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS).",
    "url": "https://finnhub.io/api/news?id=4ed1be9d42573872180d54b4640819105c2c0294a66714183c63aa26d3ddac80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734606000,
      "headline": "Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy",
      "id": 132055346,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, December 19, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS).",
      "url": "https://finnhub.io/api/news?id=4ed1be9d42573872180d54b4640819105c2c0294a66714183c63aa26d3ddac80"
    }
  },
  {
    "ts": null,
    "headline": "2 Unstoppable Stocks to Buy and Hold for the Next Decade",
    "summary": "What do Apple (NASDAQ: AAPL) and Vertex Pharmaceuticals (NASDAQ: VRTX) have in common?  The former is a consumer tech leader while the latter operates in the biotech industry.  Apple and Vertex Pharmaceuticals have outperformed the market over the past decade, and even longer.",
    "url": "https://finnhub.io/api/news?id=5e1ed4cc2cc6d9ac8bb9ef614bf12151e7c792ff6380628517ec3c529d3be84a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734600000,
      "headline": "2 Unstoppable Stocks to Buy and Hold for the Next Decade",
      "id": 132055347,
      "image": "https://g.foolcdn.com/editorial/images/800686/person-holding-a-smartphone-and-a-mug.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "What do Apple (NASDAQ: AAPL) and Vertex Pharmaceuticals (NASDAQ: VRTX) have in common?  The former is a consumer tech leader while the latter operates in the biotech industry.  Apple and Vertex Pharmaceuticals have outperformed the market over the past decade, and even longer.",
      "url": "https://finnhub.io/api/news?id=5e1ed4cc2cc6d9ac8bb9ef614bf12151e7c792ff6380628517ec3c529d3be84a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial",
    "summary": "By Chris Wack Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that...",
    "url": "https://finnhub.io/api/news?id=294364effa3d0192dec1b49cbfc731614fe3b80a56bd5fd17d8cfb7f0d955ae9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734593174,
      "headline": "Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial",
      "id": 132049931,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "By Chris Wack Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that...",
      "url": "https://finnhub.io/api/news?id=294364effa3d0192dec1b49cbfc731614fe3b80a56bd5fd17d8cfb7f0d955ae9"
    }
  }
]